Teladoc Health Files 8-K on Operations and Financial Condition

Ticker: TDOC · Form: 8-K · Filed: 2024-02-20T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, results-of-operations, SEC-filing

TL;DR

**Teladoc Health just dropped an 8-K on its financials, so keep an eye out for the details!**

AI Summary

Teladoc Health, Inc. filed an 8-K on February 20, 2024, to report on its results of operations and financial condition, as well as to include financial statements and exhibits. The filing indicates that the earliest event reported was also on February 20, 2024. The company, incorporated in Delaware with IRS number 04-3705970, maintains its principal executive offices at 2 Manhattanville Road, Suite 203, Purchase, NY 10577.

Why It Matters

This filing provides an update on Teladoc Health's financial performance and operational status, which is crucial for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial results and does not indicate any immediate new risks.

Key Players & Entities

FAQ

What was the date of the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on February 20, 2024.

What items of information are included in this 8-K filing?

The 8-K filing includes information on Results of Operations and Financial Condition, and Financial Statements and Exhibits.

Where are Teladoc Health, Inc.'s principal executive offices located?

Teladoc Health, Inc.'s principal executive offices are located at 2 Manhattanville Road, Suite 203, Purchase, NY 10577.

What is Teladoc Health, Inc.'s IRS Employer Identification Number?

Teladoc Health, Inc.'s IRS Employer Identification Number is 04-3705970.

In which state is Teladoc Health, Inc. incorporated?

Teladoc Health, Inc. is incorporated in Delaware.

From the Filing

0001477449-24-000017.txt : 20240220 0001477449-24-000017.hdr.sgml : 20240220 20240220161501 ACCESSION NUMBER: 0001477449-24-000017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240220 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 24653469 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20240220.htm 8-K tdoc-20240220 FALSE 0001477449 0001477449 2023-07-25 2023-07-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 20, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification Number) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ Item 2.02.    Results of Operations and Financial Condition. On February 20, 2024, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the fourth quarter and full year 2023. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor sha

View on Read The Filing